- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Meiji Yasuda Asset Management Reduces Incyte Corporation Stake
Institutional investor trims position in biopharmaceutical company
Mar. 9, 2026 at 10:05am
Got story updates? Submit your updates here. ›
Meiji Yasuda Asset Management Co Ltd. has reduced its stake in Incyte Corporation (NASDAQ:INCY) by 29.2% in the third quarter, according to a disclosure with the Securities & Exchange Commission. The firm now owns 27,630 shares of the biopharmaceutical company's stock, valued at $2.34 million.
Why it matters
This filing provides insight into the investment activity of Meiji Yasuda Asset Management, a major institutional investor. Changes in large investor positions can signal shifts in market sentiment around a company's stock.
The details
Meiji Yasuda Asset Management sold 11,408 shares of Incyte during the third quarter, reducing its total position to 27,630 shares. The firm cited unspecified reasons for the reduction in its Incyte holdings.
- Meiji Yasuda Asset Management filed the 13F disclosure for the third quarter of 2026.
The players
Meiji Yasuda Asset Management Co Ltd.
A Japanese asset management firm that invests in various sectors, including the biopharmaceutical industry.
Incyte Corporation
A Wilmington, Delaware-based biopharmaceutical company focused on developing novel therapies in oncology and inflammation.
The takeaway
This filing indicates that Meiji Yasuda Asset Management has reduced its exposure to Incyte Corporation, potentially signaling a shift in the firm's outlook on the biopharmaceutical company's prospects. Investors will likely monitor any further changes in large institutional positions as a gauge of market sentiment around Incyte.
Wilmington top stories
Wilmington events
Apr. 12, 2026
Future Stars ShowApr. 14, 2026
Zack Keim x David Shane: The More Love TourApr. 14, 2026
Wilmington Blue Rocks vs. Hub City Spartanburgers




